Anti-CD123 humanized single-chain antibody and application thereof

A single-chain antibody and antigen technology, applied in the field of genetic engineering, can solve the problem of antibodies losing antigen-binding activity and achieve the effects of enhancing persistence, safety, good stability, and reducing immunogenicity
CN110950954AActive Publication Date: 2020-04-03CHONGQING PRECISION BIOTECH CO LTD
10 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CHONGQING PRECISION BIOTECH CO LTD
Publication Date
2020-04-03

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the field of gene engineering, and particularly relates to an anti-CD123 humanized single-chain antibody and an application thereof. The light-chain amino acid sequences of the single-chain antibody for identifying a CD123 antigen are shown as SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 and SEQ ID NO: 7. The heavy chain amino acid sequences of the single-chain antibody are shown as SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 and SEQ ID NO: 8. The invention provides a stable and suitable anti-CD123 humanized single-chain antibody (scFv) which is used for preparing a CAR structure. The binding specificity and affinity of the scFv are reserved, and the stability and safety of CAR-T in vivo are guaranteed. After expression in immune cells, not only can tumor target cells expressing the CD123 antigen be effectively removed, but also no toxic effect is caused to tumor cells expressing a negative antigen (not expressing CD123). Moreover, the positive rate of the CD123-targeting CAR in the cell culture process of a patient can be maintained, and the CD123-targeting CAR can be proliferated for a long time after being stimulated by a target antigen and can be used for targeting treatment of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of genetic engineering, and in particular relates to an anti-CD123 humanized single-chain antibody and its application. Background technique

[0002] CD123, also known as interleukin-3 receptor α chain (IL-3Rα), is highly expressed in leukemia stem cells or leukemia immature cells, and is not or lowly expressed in normal hematopoietic stem cells. It is a leukemia-associated antigen and a specific antigen for acute myeloid leukemia. Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem / progenitor cells, characterized by abnormal proliferation of primitive and immature myeloid cells in bone marrow and peripheral blood. Timely treatment is often life-threatening; although conventional induction chemotherapy can alleviate AML, it cannot prevent the recurrence of AML and the high mortality rate of relapsed patients. However, the conventional treatment of AML has not changed for 50 years, and it...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More